These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 31937586

  • 1. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials.
    Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M, Rovatirelin Study Group.
    J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):254-262. PubMed ID: 31937586
    [Abstract] [Full Text] [Related]

  • 2. Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya.
    Ijiro T, Yaguchi A, Yokoyama A, Abe Y, Kiguchi S.
    Eur J Pharmacol; 2020 Sep 05; 882():173271. PubMed ID: 32534077
    [Abstract] [Full Text] [Related]

  • 3. Rovatirelin ameliorates motor dysfunction in the cytosine arabinoside-induced rat model of spinocerebellar degeneration via acetylcholine and dopamine neurotransmission.
    Ijiro T, Yaguchi A, Yokoyama A, Kiguchi S.
    Clin Exp Pharmacol Physiol; 2022 Sep 05; 49(9):950-958. PubMed ID: 35637550
    [Abstract] [Full Text] [Related]

  • 4. Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
    Feil K, Adrion C, Boesch S, Doss S, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Steiner KM, Stendel C, Timmann D, Naumann I, Mansmann U, Strupp M, ALCAT Study Group.
    JAMA Netw Open; 2021 Dec 01; 4(12):e2135841. PubMed ID: 34905009
    [Abstract] [Full Text] [Related]

  • 5. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.
    Feil K, Adrion C, Teufel J, Bösch S, Claassen J, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Stendel C, Uslar E, van de Warrenburg B, Berger I, Naumann I, Bayer O, Müller HH, Mansmann U, Strupp M.
    BMC Neurol; 2017 Jan 10; 17(1):7. PubMed ID: 28068987
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial.
    Coarelli G, Heinzmann A, Ewenczyk C, Fischer C, Chupin M, Monin ML, Hurmic H, Calvas F, Calvas P, Goizet C, Thobois S, Anheim M, Nguyen K, Devos D, Verny C, Ricigliano VAG, Mangin JF, Brice A, Tezenas du Montcel S, Durr A.
    Lancet Neurol; 2022 Mar 10; 21(3):225-233. PubMed ID: 35063116
    [Abstract] [Full Text] [Related]

  • 7. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
    Romano S, Coarelli G, Marcotulli C, Leonardi L, Piccolo F, Spadaro M, Frontali M, Ferraldeschi M, Vulpiani MC, Ponzelli F, Salvetti M, Orzi F, Petrucci A, Vanacore N, Casali C, Ristori G.
    Lancet Neurol; 2015 Oct 10; 14(10):985-91. PubMed ID: 26321318
    [Abstract] [Full Text] [Related]

  • 8. Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system.
    Ijiro T, Nakamura K, Ogata M, Inada H, Kiguchi S, Maruyama K, Nabekura J, Kobayashi M, Ishibashi H.
    Eur J Pharmacol; 2015 Aug 15; 761():413-22. PubMed ID: 26142830
    [Abstract] [Full Text] [Related]

  • 9. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations.
    Sobue I, Takayanagi T, Nakanishi T, Tsubaki T, Uono M, Kinoshita M, Igata A, Miyazaki M, Yoshida M, Ando K.
    J Neurol Sci; 1983 Oct 15; 61(2):235-48. PubMed ID: 6417282
    [Abstract] [Full Text] [Related]

  • 10. Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy.
    Gazulla J, Benavente I.
    Acta Neurol Scand; 2007 Oct 15; 116(4):235-8. PubMed ID: 17824901
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of thyrotropin releasing hormone (TRH) on motor execution and motor adaptation process in patients with spinocerebellar degeneration.
    Shimizu T, Tsutsumi R, Shimizu K, Tominaga N, Nagai M, Ugawa Y, Nishiyama K, Hanajima R.
    J Neurol Sci; 2020 Aug 15; 415():116927. PubMed ID: 32474221
    [Abstract] [Full Text] [Related]

  • 12. High-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy.
    Vural M, Ozekmekçi S, Apaydin H, Altinel A.
    Mov Disord; 2003 Apr 15; 18(4):457-9. PubMed ID: 12671958
    [Abstract] [Full Text] [Related]

  • 13. Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration.
    Mori M, Adachi Y, Mori N, Kurihara S, Kashiwaya Y, Kusumi M, Takeshima T, Nakashima K.
    J Neurol Sci; 2002 Mar 30; 195(2):149-52. PubMed ID: 11897246
    [Abstract] [Full Text] [Related]

  • 14. D-cycloserine for the treatment of ataxia in spinocerebellar degeneration.
    Ogawa M, Shigeto H, Yamamoto T, Oya Y, Wada K, Nishikawa T, Kawai M.
    J Neurol Sci; 2003 Jun 15; 210(1-2):53-6. PubMed ID: 12736088
    [Abstract] [Full Text] [Related]

  • 15. [Physostigmine in treatment of cerebellar ataxia].
    Aschoff JC, Kailer NA, Walter K.
    Nervenarzt; 1996 Apr 15; 67(4):311-8. PubMed ID: 8684510
    [Abstract] [Full Text] [Related]

  • 16. Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue.
    Kobayashi K, Abe Y, Harada H, Oota E, Endo T, Takeda H.
    Xenobiotica; 2019 Jan 15; 49(1):106-119. PubMed ID: 29300135
    [Abstract] [Full Text] [Related]

  • 17. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial.
    Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, Pontieri FE, Vanacore N, Salvetti M.
    Neurology; 2010 Mar 09; 74(10):839-45. PubMed ID: 20211908
    [Abstract] [Full Text] [Related]

  • 18. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
    Trouillas P, Xie J, Adeleine P, Michel D, Vighetto A, Honnorat J, Dumas R, Nighoghossian N, Laurent B.
    Arch Neurol; 1997 Jun 09; 54(6):749-52. PubMed ID: 9193210
    [Abstract] [Full Text] [Related]

  • 19. Choline chloride in the treatment of cerebellar and spinocerebellar ataxia.
    Livingstone IR, Mastaglia FL, Pennington RJ, Skilbeck C.
    J Neurol Sci; 1981 May 09; 50(2):161-74. PubMed ID: 7229661
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 09; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.